MTA1 and prostate cancer: Pterostilbene reduced MTA1-dependent cell survival and metastasis in prostate cancer by inhibiting MTA1 expression, disrupting the MTA1-histone deacetylase complex, and restoring PTEN expression (Dhar et al., 2016; Levenson, 2022a; Levenson, 2022b; Kocabas and Sanlier, 2023).